The past 2 decades have seen a proliferation of transcatheter mitral valve (MV) therapies, which are less invasive and distinct from surgical MV repair or replacement. The commonly used MV transcatheter therapies include (1) percutaneous mitral balloon commissurotomy (PMBC) for rheumatic mitral stenosis; (2) edge-to-edge repair with the MitraClip for mitral regurgitation; (3) valve-in-valve implantation in bioprosthetic MV, native MV, or mitral ring; and (4) closure of paravalvular leaks (PVLs). This article will focus on the use of echocardiography in the diagnosis, patient selection, procedural guidance, and postprocedural follow-up for PMBC, with notes on the role of transesophageal echocardiography in transcatheter interventions for prosthetic valve degeneration and PVL closure.
Introduction
In patients undergoing percutaneous mitral valve (MV) therapies, echocardiography plays a crucial role. The commonly used MV transcatheter therapies include (1) percutaneous mitral balloon commissurotomy (PMBC) for rheumatic mitral stenosis (MS); (2) edge-to-edge repair with the MitraClip for mitral regurgitation (MR); (3) valvein-valve (ViV) in bioprosthetic MV, native MV, or mitral ring; and (4) closure of paravalvular leaks (PVLs). This article will focus on the use of echocardiography in diagnosis, patient selection, procedural guidance, and postprocedural follow-up for PMBC, with notes on the role of transesophageal echocardiogram (TEE) in transcatheter interventions for prosthetic valve degeneration and PVL closure. The MitraClip and the dedicated transcatheter mitral therapies will be covered elsewhere in this edition.
Percutaneous Mitral Balloon Commissurotomy
Rheumatic heart disease is the most common cause of MS. Commissural fusion is the predominant mechanism of valvular obstruction in rheumatic MS (Figure 1 ), and it lends itself to balloon commissurotomy. In fact, PMBC is the treatment of choice for properly selected rheumatic MS patients. 1, 2 Since its introduction in 1984 by Inoue et al, 3 it has been proven to be a safe and effective alternative to surgery with good short-and long-term results in properly selected patients. [4] [5] [6] [7] 
Indications
Based on the most recent (2014) American College of Cardiology (ACC)/American Heart Association (AHA) valvular heart disease guidelines, 2 the classification of MS severity is outlined in Table 1 . The indications for intervention are shown in Figure 2 .
Mitral Valve Area
Mitral valve area (MVA) can be obtained from 2-dimensional (2D) or 3D planimetry, from pressure half-time (PHT), from the continuity equation, or by the proximal isovelocity surface area (PISA).
Echocardiographic Determination of MVA Direct Planimetry
A short axis of the MV is obtained from a parasternal view by transthoracic echocardiogram (TTE) or a deep transgastric image by TEE ("fish mouth" appearance). The inner rim of the orifice is traced in middiastole to obtain the MVA. The correlation of direct planimetry with surgical measurements is excellent (r = 0.92). 8 The narrowest orifice in MS is at the level of the leaflet tips. If measured above the leaflet tips, the area can be overestimated. This limitation can be overcome by the use of 3D echocardiography, which provides accurate assessment of the diastolic Reprinted with permission from Nishimura et al (table 13) . 2(pe553) ©2014 American Heart Association, Inc. The transmitral mean pressure gradient should be obtained to further determine the hemodynamic effect of MS. In severe MS, it is usually between 5 and 10 mm Hg. It was excluded from the criteria for severity because of its variability with heart rate and forward flow.
MVA.
9 Full-volume images of the MV can be obtained from either parasternal or apical TTE views or from the 4-chamber view on TEE. A volumetric pyramid is scanned, and images are displayed as intersecting orthogonal views. The data can also be analyzed in real time live 3D mode. 3D echocardiography provides reproducible and accurate assessment of the diastolic MVA at the level of the narrowest orifice.
10,11

PHT and Deceleration Time
PHT is based on the concept that the rate of pressure decline across the stenotic mitral orifice is determined by the cross-sectional area of the orifice. It is defined as the time it takes for the diastolic pressure gradient across the MV to decrease by half. The smaller the orifice, the slower the rate of pressure decline and the greater the PHT. The PHT method assumes that the rate of decrease in the transmitral gradient is only affected by MVA, but changes in loading conditions significantly affect PHT. Therefore, this is not a reliable method to estimate MVA in the periprocedural period. Severe aortic insufficiency will increase the left-ventricular diastolic pressure, resulting in shorter PHT and false overestimation of mitral area. Changes in heart rate, atrial fibrillation (AF), and the presence of an atrial septal defect (ASD) significantly affect the PHT. In the pericommissurotomy period (24-72 hours), there is increase in left-ventricular filling and decrease in compliance, and therefore PHT should not be used to estimate the MVA. 12 Deceleration time (DT) is the time required for the peak transmitral velocity to decrease to the zero baseline. PHT can be calculated by multiplying the DT by 0.29 because it is 29% of the DT when the velocity decline is linear. 12, 13 The interrelationships between MVA, PHT, and DT can be expressed by the following formulas, where time is in milliseconds and the MVA is expressed in centimeter squared 14, 15 : 
2(pe554)
Continuity Equation MVA
The continuity principle is based on the principle of conservation of mass and can be applied to the mitral orifice to determine the MVA. The proximal and distal stroke volume across the stenotic MV must be equal:
where VTI is the velocity time integral. Stroke volume can be determined from the left-ventricular outflow tract crosssectional area and VTI. The MVA is then calculated as shown in Equation 3 . The continuity principle can only be used to calculate MVA in the absence of aortic regurgitation or MR.
Proximal Isovelocity Surface Area
The PISA principle is based on the fact that as flow converges toward an orifice, it can be thought of as forming hemispheric shells of increasing velocity with decreasing radius. PISA measurements are made by color flow Doppler in the 4-chamber view. The color Doppler flow parameters are optimized to visualize a well-defined hemisphere on the left atrial side. 9 The color Doppler baseline is shifted in the direction of flow (ie, toward the left ventricle). Because the mitral inflow is funnel shaped, an angle correction of α/180 is applied to the equation. Thus, the formula for calculating MVA PISA is
MVA
Aliasing velocity Peak mitral velocity
where r is the radius of the flow convergence hemisphere in centimeters, the aliasing and mitral velocities are in centimeters per second, and α is the opening angle of the mitral leaflets. The peak mitral velocity is measured using continuous wave Doppler. The aliasing velocity is the upper velocity of the color Doppler map, typically 25 to 40 cm/s. Although technically demanding, this method can also be applied in patients with MR.
Gradients
The gradients should be measured at normal heart rates (60-70 bpm) because elevated heart rates can lead to elevation in gradient. From the standard 4-chamber view, the gradient is assessed by placing the sample volume of the pulse wave Doppler at the tips of the MV leaflets. The diastolic transmitral gradient is traced, and the mean gradient is derived using the simplified Bernoulli equation. 16 In patients with AF, the mean gradient should be averaged from multiple (5) beats. The gradient is dependent on transmitral flow and changes in loading conditions, and the compliance of the left heart. The ACC/AHA guidelines, therefore, recommend assessing the severity of MS in patients who are in AF based on the MVA. 17 and ACC/AHA 2014 2 ; the 2017 updated valve guideline did not touch on MS) do not include gradients as cutoff points for valve severity. Instead, the emphasis is on valve area (both ACC and ESC) and PHT (ACC), which is indicated in the treatment algorithms in both guidelines. According to Sugeng et al, 18 3D planimetry is the most accurate method to determine MVA, followed by the PISA and PHT methods. The mean gradient and transvalvular velocity, however, do seem to predict prognosis.
Patient Selection
Data from the early surgical and autopsy experience from the 1950s had shown that leaflet immobility, subvalvular apparatus changes, and commissural fusion contributed to valve stenosis. [19] [20] [21] Based on some of these features, a semiquantitative echo score was devised by Wilkins et al 22 to predict the success of the PMBC. The score is based on 4 valve characteristics: leaflet thickening, subvalvular change, leaflet mobility, and valve calcification ( Table 2) . A MV with a score of 8 or less in the absence of moderate MR is deemed the best candidate for PMBC. The score does not take into account commissural fusion, which is an important determinant of successful valvuloplasty. 21, 23 Scoring based on real-time 3D transthoracic echocardiography showed high reproducibility with good interobserver and intraobserver agreement. It seemed to be superior for detection of calcification and commissural splitting. 24 A 2D TTE is a prerequisite prior to PMBC. It helps understand etiology, severity, pliability of the valve for PMBC, and upstream hemodynamic effects. The above information can also be obtained from a TEE. A TEE is also essential prior to PMBC to evaluate the left-atrial appendage for presence of thrombus.
Left Atrium and Appendage
MS is a pressure overload condition leading to left-atrial enlargement. The left atrium can be extremely enlarged in patients with MS. Low flow rate and AF leads to stasis of blood and thrombus formation. In 2% of patients, leftatrial appendage thrombus is reported even when the patient is in sinus rhythm. 25 Left-atrial appendage thrombus formation should be excluded prior to PMBC with a TEE (Figure 3) . During the procedure, manipulation with wires and catheters can lead to embolization of the thrombus and, hence, its presence needs to be excluded.
Pulmonary Circulation and Right Heart
The elevated left-atrial pressure is transmitted back to the pulmonary veins, which initially leads to pulmonary venous hypertension. If MS is not corrected at this stage, it leads to pulmonary arterial hypertension and, later, fixed pulmonary hypertension. This leads to right atrial and ventricular enlargement, which can manifest as right heart failure. Pulmonary artery systolic pressure can be estimated by using the simplified Bernoulli equation: 4 × (tricuspid regurgitation (TR) jet velocity) 2 + Right-atrial pressure. 26 The right-atrial pressure can be estimated from the IVC size and collapsibility with respiration or obtained directly from the CVP. It is important to note that in patients with isolated MS, the left-ventricular size and function is normal. In patients who have coexisting mitral insufficiency and/or aortic insufficiency, the left ventricle size and function can be affected.
Procedure
Patients whose echo demonstrates pliable MV (with Wilkins score <8), less than moderate MR, an absence of LA appendage thrombus, and absence of any prior interatrial septal device are candidates for PMBC. Next, we describe the PMBC procedure using the Inoue balloon technique.
The procedure can be performed either under deep sedation or general anesthesia. If TEE guidance is used during the procedure, general anesthesia is preferred. Using the femoral approach, a 9 Fr sheath is inserted into the femoral vein and a 5 Fr sheath in the femoral artery. A pigtail catheter is inserted into the left ventricle from the femoral artery. The patient should be heparinized with a weight-based heparin dose of 100 IU/kg.
Transseptal puncture is the key step of the procedure. Imaging guidance during the procedure can be provided by either intracardiac echocardiography (ICE) or TEE. In a study on 55 consecutive patients, there was no difference in the procedural outcomes between TEE-and ICE-guided transseptal puncture. 27 The principles and concerns of TEE imaging during this step are identical in all structural heart procedures involving crossing the interatrial septum (IAS). The puncture can be performed by either using the Brockenbrough needle or by using radio frequency energy (Baylis Transseptal Needle, Baylis Medical, Montreal, QC, Canada). The catheter and the needle are advanced into the superior vena cava under fluoroscopy and echo guidance. The typical position for transseptal puncture is the inferior and mid-to posterior part of the septum. In the bicaval view, the transseptal sheath and catheter are pulled slowly inferiorly from the superior vena cava toward the inferior-to midportion of the septum. A leftward tenting of the interatrial septum can be seen when the transseptal needle makes contact with the septum (Figure 4 ). Next, a modified short-axis view at the aortic valve level in the midesophagus is used to position the transseptal access sheath posteriorly (away from the aortic valve) with a clockwise rotation. Another useful midesophagus TEE view for transseptal puncture guidance is an X-plane/ biplane view obtained from the bicaval view through the tented septum, simultaneously demonstrating a modified short-axis view at the aortic valve level. This allows superior-inferior and anterior-posterior orientation. It should be kept in mind that the biplane view would give an orthogonal (90°) view from the bicaval image plane and, therefore, would display the aortic valve on the right side of the clip ( Figure 4A ).
It is important for the echocardiographer to visualize the fluoroscopy screen during the procedure because the presence of pacemakers or catheters in the right atrium can be misinterpreted for the transseptal sheath. It is also important to carefully note the positions of these devices prior to advancement of the catheter and needle into the SVC, to avoid confusion. Live 3D or 3D zoom can also be used to guide the procedure, although the use of 3D images is not necessary for the success of the procedure. Simultaneous live fluoroscopy can help visualize the relationship of the TEE probe with the sheath in the right atrium. It is also important to note that communication during the key steps of the procedure is paramount, and the use of common terminology by the imaging physician and the interventionist is crucial.
The Inoue balloon catheter is a 12 Fr catheter that has a plastic mesh over a latex balloon. Balloon size is selected using the formula Balloon size (mm) = [Height (cm)/10] + 10. 28 It has 2 lumens: one for the passage of the wire and the other for inflating the balloon. The balloon is available in 4 sizes (24, 26, 28 , and 30 mm). Right anterior oblique view on fluoroscopy is the preferred view for the procedure. After the transseptal puncture, a stiff coiled tip wire is inserted into the left atrium. The femoral venous site and the septum are dilated with a 14 Fr dilator, and a 14 Fr sheath is inserted in the left femoral vein. The balloontipped Inoue catheter is advanced into the left atrium over the stiff wire. Next, the wire is exchanged for a curved stylet, and the balloon is partially inflated and floated across the MV to prevent entrapment of balloon into the subvalvular apparatus. TEE can aid with the proper placement of the balloon ( Figure 5A ). Once in the left ventricle, the distal half of the balloon is inflated fully and pulled back against the MV. At this point, the balloon is inflated fully across the MV for a few seconds, then rapidly deflated ( Figure 5B ). The balloon should be inflated 4 mm below the recommended maximum range. In vitro studies suggest that the principal mechanisms leading to successful PMBC include valve stretching and commissural splitting. 29 The degree of MR and residual gradient should be checked after each inflation. If there is a 50% reduction in the MV gradient and MVA measured by planimetry is greater than 1.5 cm 2 , the procedure is considered successful. If the above criteria are not met and there is no worsening of MR, then the balloon can be readvanced and inflated to a 1-mm larger size than the prior inflation. Careful TEE evaluation of the MVA with planimetry, gradient, and degree of MR should be performed. After the balloon is withdrawn across the septum, residual atrial shunt across the transseptal puncture site should be documented. The pericardial space should be evaluated intermittently during the procedure and again at the end to assess for any evidence of pericardial effusion. A figure-of-8 stitch is then deployed to close the femoral venipuncture site. A TTE should be obtained the following day before discharge to confirm the Doppler findings, valve area, and MR and also to reassess the pericardial space.
Complications
The safety of PMBC is related to operator experience. Following a step-by-step approach under expert imaging guidance is key. The procedural mortality is around 0.12% to 1.4%, with higher rates (up to 2.7%) reported in early series. 28, [30] [31] [32] [33] The majority of deaths seem to be related to perforation of the left ventricle. 28, 30, 31, 33 According to Glazier and Turi, 28 these perforations have occurred with catheters other than the Inoue catheter.
1. Pericardial tamponade is reported in 0.8% to 4% of cases. 28 Transseptal puncture and left-atrial perforation, and rarely left-ventricular perforation, can lead to hemopericardium and tamponade. Careful hemodynamic monitoring and imaging of the pericardial sac can lead to early identification. Prompt pericardiocentesis will help stabilize the patient. 2. Systemic embolization and, in particular, stroke can occur in 1%-5% of patients. 34 Catheter thrombus, left-atrial thrombus, and iatrogenic air embolism lead to systemic embolization. Preprocedure TEE, systemic anticoagulation during the procedure, and meticulous flushing techniques can help prevent thromboembolism. 28 3. Severe MR requiring surgical repair has been reported in the range from 0.8% 35 to 5%. 28 4. Residual atrial septal defect with significant shunt fraction is rare.
28,36
Postprocedural outcomes
Long-term data for PMBC suggest that in appropriately selected patients (echo score < 8), the estimated freedom from death, MV replacement, and heart failure ranges from 57% to 75%. 28 When compared with surgical commissurotomy, PMBC results in a greater MVA at 3 years. The restenosis rate at 32 ± 14 months has been reported as 5.2%
32 and the 7-year restenosis rate as 33%. 28 There is a decrease in pulmonary artery pressures and vascular resistance over a period of 3 years. A recent report of a Korean cohort of PMBC patients followed for 10 to 20 years concluded that there were 2 independent predictors of longterm reintervention, stroke, and cardiovascular death: echo score >8 and post-PMBC MVA ⩽1.76 cm 2 .
35
Pregnancy and PBMC
Severe MS can sometimes first be diagnosed during pregnancy because of the increase in circulating blood volume. The 2014 AHA/ACC valve guidelines state that percutaneous mitral commissurotomy is a reasonable choice in this patient population (Class IIa recommendation, level of evidence: B) 2 as long as the following conditions are met: the valve area is ⩽1.5 cm 2 , valve morphology is favorable, and the patient has NYHA class III or IV heart failure symptoms despite medical therapy. Favorable valve morphology for PBMC is considered the absence of severe leaflet calcification and thickening, commissural calcification, or subvalvular fusion because the presence of these factors can increase the risk of severe postprocedural MR and the need for urgent surgical intervention.
2 PBMC has been shown to be associated with lower or no maternal mortality compared with surgical commissurotomy. [37] [38] [39] It has also been shown to result in lower fetal mortality. 37, 40 It is not clear whether modern surgical MV techniques would be associated with a mortality rate similar to that reported for surgical commissurotomy in pregnant patients in the 1970s, 1980s, and 1990s, but it is worth noting that in the much referenced report by de Souza et al, 37 the fetal mortality rate in the surgical group was 38%.
PBMC should be performed in the second trimester.
41,42
The Inoue technique is the preferred method. 43 It is possible to perform the procedure under monitored anesthesia care. Heart rate control with metoprolol, 2 avoidance of AF, and the potential for aortocaval compression are important considerations during the procedure. Radiation safety to the fetus is key, which necessitates using minimal radiation and complete abdominal lead shielding. 38, 44 ICE for transseptal puncture and the use of TTE to measure the MV gradient may be preferred over TEE, and appropriate aspiration precautions should be taken as in any pregnant patient undergoing any type of anesthetic.
Bioprosthetic MS and/or Regurgitation
Prosthetic valve stenosis may be caused by thrombus, pannus, or calcific degeneration. In prosthetic MS, TEE is an essential part of the evaluation. Suggested features of prosthetic MV stenosis include peak transmitral velocity of 2.5 m/s or greater, mean gradient greater than 10 mm Hg, effective orifice area of the MV (as measured by continuity equation) less than 1 cm 2 , and PHT greater than 200 ms. The ratio of VTI obtained across the prosthetic MV to that of the left ventricular outflow tract (LVOT), if greater than 2.5, suggests prosthetic stenosis. A comprehensive assessment is essential because tachycardia, high-output states, or patient prosthesis mismatch can lead to these values being abnormal in the absence of true stenosis. Because each valve has its own echocardiographic and physiological fingerprint, it is important to know the type and size of prosthetic MV as well as the immediate postoperative Doppler echocardiography data, if available. This underscores the importance of complete intraoperative TEE evaluation and documentation.
Case reports describing the role of balloon valvuloplasty in patients with bioprosthetic stenosis have reported some success. 45, 46 Because the mechanism of prosthetic stenosis is different from that in rheumatic MS, balloon valvuloplasty, which results in commissural splitting, is not the treatment of choice.
Recently, there has been growing interest in the use of transcatheter aortic prostheses, specifically the Edwards Sapien valve, in the mitral position by percutaneous approach in patients with bioprosthetic MS or regurgitation. 47 The US Food and Drug Administration approved Edwards SAPIEN 3 (Edwards Lifesciences Corporation, Irvine, California) transcatheter heart valve for mitral ViV procedures in June 2017, based on the national Society of Thoracic Surgery/ACC transcatheter valve therapy registry data outcomes. 48 In the largest published series to date, the most common approach for the implantation of a transcatheter valve in a degenerated MV has been the transapical approach. 47 Only 33% were performed via a transvenous septal approach. 49 Preliminary data from the ViV International Data Registry suggest that the transseptal approach may be the preferred one because the transapical patients experienced less improvement in their postprocedural left-ventricular ejection fraction. 50 Data from the transapical TAVR experience has shown higher mortality compared with the transfemoral approach for that procedure, but it is not clear that this can be extrapolated to the transcatheter mitral ViV population because in the TAVR population, the transapical approach may be reflective of a higher baseline risk resulting from more severe vascular disease. 47 Preprocedural planning with computed tomography scan is essential. This helps evaluate the inner diameter of the prosthetic valve, predict neo left-ventricular outflow tract obstruction, and suggest the fluoroscopic deployment angle. The valve size is selected based on the true inner diameter of the prosthesis. The Valve in Valve Mitral app for Apple mobile devices (https://itunes.apple.com/us/app/ valve-in-valve-mitral/id703369667?mt=8) is a handy tool to suggest the valve size in patients with prosthetic valves or rings. Interventional echocardiography is paramount for this procedure for transseptal puncture, atrial septostomy, valve deployment, and postprocedure Doppler interrogation of the new valve. 3D TEE is useful, in particular when the anatomical alignment, or "surgeon's view," of the valve is desired. 51 Live 3D view can be used to guide device positioning and deployment.
Closure of Paramitral Paravalvular Defect
The treatment of paravalvular regurgitation (PVR) via percutaneous, catheter-based methods has been shown to be technically feasible and to reduce hemolysis and heart failure. [52] [53] [54] [55] [56] [57] [58] [59] Catheter-based closure of prosthetic valve PVR is indicated in patients who are in New York Heart Association Class III or IV heart failure, who present with intractable hemolysis, or who are at high risk for redosurgery (Class IIa, LOE: B). 60 The goal of the intervention should be no more than mild residual PVR because this correlates with successful relief of the symptoms of heart failure. 58 Devices successfully deployed for embolization of PVR include the AMPLATZER Vascular Plug 2 and 4 (Abbott, St Paul, MN; formerly St Jude Medical). 60 Both antegrade (transseptal) and retrograde (transapical) approaches have been utilized. A steerable guide catheter can facilitate the positioning of the occluder device.
Preprocedural and intraprocedural echocardiographic guidance relies on standard 2D TEE imaging as well as 3D imaging. Multiple 2D and 3D images may be required. 52, 61, 62 Because of the reliance on TEE, general anesthesia is preferable. 63 3D views of the mitral prosthesis in the anatomical position with color Doppler well demonstrate the location of the paravalvular regurgitant jet. 64 The location of the defect or defects needs to be ascertained as well as their shape (round, oblong) and size because these parameters determine the type and size of the occluder device(s) to be used. It is also important to delineate the relationship of the defect(s) to the sewing ring of the prosthetic valve. For example, larger defects that crescent around the sewing ring may be best closed with multiple smaller occluders, instead of a single larger one, because the larger devices increase the risk of impingement on the prosthetic valve as a result of overhang. More than 1 device may need to be deployed. 63 Intraprocedural TEE is useful in demonstrating complications such as malpositioning or embolization of the occluder. 63 As with any paravalvular intervention, before the completion of the procedure, the echocardiographer should evaluate the mitral prosthesis for valve function, peak and mean gradients, residual PVR, impedance of pulmonary vein flow, and residual transseptal defect.
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